Khaled Nashar, MD
Nephrology · Pittsburgh, PANPI 1124056122
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $170,652 of the $198,235 with a category attached, or 86.1%. 12 manufacturers reported payments, led by Novo Nordisk at 38.6% of the total. 2025 is the largest year on record at $81,684, 7.0 times the $11,643 reported in 2019. Among nephrology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $1231.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$76K
- AstraZeneca$62K
- Vifor Pharma, Inc.$45K
- Bayer$13K
- Ardelyx, Inc.$248
- Medtronic$147
- plus $521 from 6 others
What the payments were for
- Consulting fees$1,9601%
- Speaking & faculty fees$170,65286%
- Travel & lodging$19,30210%
- Food & beverage$6,3213%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $76,422 |
| AstraZeneca(2 entities) | 54 | $62,111 |
| Vifor Pharma, Inc. | 37 | $45,293 |
| Bayer | 9 | $13,492 |
| Ardelyx, Inc. | 2 | $248 |
| Medtronic | 1 | $147 |
| Astrazeneca UK Limited | 1 | $130 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Merck | 1 | $119 |
| Amgen | 1 | $109 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| Akebia Therapeutics Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$198,235 in reported general payments places this provider in the 95th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 29 | $31,992 |
| FarxigaDapagliflozin Propanediol | 22 | $13,014 |
| Valganciclovir Hcl | 19 | $3,594 |
| Sevelamer Carbonate | 14 | $3,244 |
| Nifedipine ErNifedipine | 52 | $425 |
| Prednisone | 53 | $383 |
| Dapsone | 13 | $357 |
| Metolazone | 15 | $335 |
| Amlodipine Besylate | 53 | $279 |
| Atorvastatin Calcium | 16 | $235 |
| Bumetanide | 11 | $233 |
| Doxazosin Mesylate | 48 | $224 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 46 | $220 |
| Furosemide | 49 | $211 |
| Hydralazine Hcl | 26 | $204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $62,111 | $13,01422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Pittsburgh
- Christopher GislerPittsburgh$757K
- Swati AroraPittsburgh$190K
- Linda FriedPittsburgh$35K
- Cary ShiwarskiPittsburgh$15K
- Fadi LakkisPittsburgh$7K
- Nelson KopytAllentown$949K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.